Cryoport (CYRX) announced a new strategic partnership with Syneos Health (SYNH). The partnership will support the global advancement of cell and gene therapies, providing the industry’s first fully integrated biopharmaceutical and supply chain solution. The new partnership couples the full suite of clinical development services offered by Syneos Health with IntegriCell, Cryoport’s platform providing standardized apheresis collection through BioLife Cellular Therapy Services, part of Takeda (TAK), cryopreservation services, risk mitigation services, logistics support, and secondary packaging.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CYRX:
